R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed

Crippa, 2021, Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology, HPB, 23, 1666, 10.1016/j.hpb.2021.04.004 Ducreux, 2015, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 26, v56, 10.1093/annonc/mdv295 2022, Pancreatic adenocarcinoma Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N. Engl. J. Med., 350, 1200, 10.1056/NEJMoa032295 Kaltenmeier, 2021, Impact of resection margin status in patients with pancreatic cancer: a national cohort study, J. Gastrointest. Surg., 25, 2307, 10.1007/s11605-020-04870-6 Demir, 2018, R0 versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer, Ann. Surg., 268, 1058, 10.1097/SLA.0000000000002345 Neoptolemos, 2001, Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial, Ann. Surg., 234, 758, 10.1097/00000658-200112000-00007 Butturini, 2008, Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials, Arch. Surg., 143, 75, 10.1001/archsurg.2007.17 Lopez, 2014, Borderline resectable pancreatic cancer: definitions and management, WJG, 20 Sugumar, 2021, The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: a systematic review and meta‐analysis, Cancer Rep., 4 Ma, 2019, Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer, JAMA Netw. Open, 2, 10.1001/jamanetworkopen.2019.9126 Suss, 2018, Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer?, Surgery, 163, 1047, 10.1016/j.surg.2017.09.022 Boyle, John, Czito, Brian, Willet, Christopher, Palta, Manisha. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J. Gastrointest. Oncol.. doi:10.3978/j.issn.2078-6891.2015.014. Oba, 2022, Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis, Br. J. Surg., 109, 450, 10.1093/bjs/znac002 Versteijne, 2020, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial, J. Clin. Orthod., 38, 1763 Janssen, 2022, Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study, J. Natl. Compr. Cancer Netw., 20, 783, 10.6004/jnccn.2022.7008 Sekigami, 2021, Intraoperative radiation mitigates the effect of microscopically positive tumor margins on survival among pancreatic adenocarcinoma patients treated with neoadjuvant FOLFIRINOX and chemoradiation, Ann. Surg Oncol., 28, 4592, 10.1245/s10434-020-09444-z